Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)
CAPS Rating:
The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.
RSS Headlines
Fool UK
Recs
Bravobevo